Predict your next investment

Government
kibowproject.jp

See what CB Insights has to offer

Investments

2

Funds

2

About KIBOW

KIBOW is a goverment investment group based out of Tokyo, Japan.

KIBOW Headquarter Location

Sumitomo Fudosan Koji-machi Building 5-1 Niban-cho, Chiyoda-ku

Tokyo, 102-0084,

Japan

81 3 5275 3762

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest KIBOW News

Kibow Biotech Announces FDA Approval Of IND To Initiate Phase II Clinical Trial Of US-APR2020 To Treat Chronic Kidney Disease St...

Apr 14, 2021

Expect to Enroll 630 Patients in this one Year Study to Begin in Q3 2021 Newtown Square, PA /PRNewswire/ - Kibow Biotech, Inc., a clinical-stage biotechnology company pioneering the discovery and development of probiotics and prebiotics (synbiotics) for the treatment of kidney diseases beyond gut health, today announced that the U.S. Food and Drug Administration (FDA) had approved the Company's Investigational New Drug Application (IND) for US-APR2020 to treat patients with Chronic Kidney Disease (CKD) stage IV. The primary efficacy endpoint for the multisite trial is to arrest the decline of estimated Glomerular Filtration Rate (eGFR) by 40% from baseline as per the American Society of Nephrology (ASN), National Kidney Foundation (NKF), and US FDA ( https://pubmed.ncbi.nlm.nih.gov/25441437/ ). "The FDA's approval of our IND is a significant milestone in transitioning Kibow Biotech from a 23-year-old kidney health supplement to a live biotherapeutic product under the Center for Biologics Evaluation and Research (CBER) and US FDA regulations," Natarajan Ranganathan, Ph.D., Chairman and Founder, Kibow Biotech, said. "We look forward to embarking on our next chapter as a phase II/III clinical-stage biopharmaceutical company, harnessing the novel "Intestinal Dialysis™" platform technology to modulate the gut microbiome with our natural proprietary pro/prebiotics (synbiotics) to address organ-specific health conditions and target unmet medical diseases. As is becoming evident, the dysbiosis of the gut microbiome is the cause of various diseases. Kibow Biotech has been a pioneer in using Pro/Prebiotics targeting gut microbiome modulation to alleviate dysbiosis in CKD/End-Stage Renal Disease (ESRD) patients. This unique and novel study is designed as a double-blind, randomized, placebo-controlled, phase II clinical trial to evaluate the effect of US-APR2020 in patients with CKD stage IV for six months and followed to continue as an open-label trial on all enrolled patients for another six months, with total completion of one year. For a summary of this study information, please see the following PDF: https://kibowpharma.com/pdf/Protocol_Summary__CKD_4_630_patients.pdf "With three specifically chosen probiotic strains of highly beneficial targeted bacteria, we selected this unique blend based on our decades of clinically tested and consumers' very positive feedback on the kidney health supplement. Our science has demonstrated the ability of this unique blend to improve the quality of life in people with kidney diseases," added Dr. Ranganathan. "We believe the future of kidney care will be the use of synbiotics in modulating the gut microbiome to improve better outcomes and quality of life for CKD/ESRD patients worldwide." Clinical site initiation activities are underway for the phase II clinical trial of US-APR2020. The Company anticipates the enrollment to begin in the third quarter of 2021. In this regard, Kibow recently has launched a separate wholly-owned pharmaceutical subsidiary division, called Kibow Pharmaceuticals, LLC. ( http://kibowpharma.com/ ). We acknowledge the guidance and services of Mukesh Kumar, Ph.D., RAC, our strategic regulatory consultant, and his team from Brij Strategic Consultations, LLC, MD. ( www.FDAmap.com ). About US-APR2020 US-APR2020 is a natural probiotics formulation that metabolizes nitrogenous waste, which generally diffuses from the circulating bloodstream into the bowel. When these waste products accumulate in high concentrations in the blood, they become highly toxic and can cause severe damage to many organ systems if they are not properly excreted. US-APR2020 utilizes nitrogenous wastes as nutrients. As probiotics grow and multiply, they consume more nitrogenous waste and effectively maintain healthy kidney function. About Kidney Disease Globally, over 800 million patients are affected with CKD, increasing by about 7% per year. In the United States, 37 million adults are estimated to have chronic kidney disease , and approximately 90 percent do not know they have it. 1 in 3 adults in the U.S. is at risk for chronic kidney disease. Risk factors for kidney disease include diabetes , high blood pressure , heart disease , obesity , and family history. Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander are at increased risk for developing the disease. Black or African American people are almost four times more likely than Whites to have kidney failure. Hispanic or Latino people are 1.3 times more likely than non-Hispanic or non-Latino people to have kidney failure (Source: NKF).

KIBOW Investments

2 Investments

KIBOW has made 2 investments. Their latest investment was in A's Child as part of their Corporate Minority on September 9, 2021.

CBI Logo

KIBOW Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/13/2021

Corporate Minority

A's Child

$0.45M

Yes

1

10/9/2018

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/13/2021

10/9/2018

Round

Corporate Minority

Seed

Company

A's Child

Subscribe to see more

Amount

$0.45M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

10

KIBOW Fund History

2 Fund Histories

KIBOW has 2 funds, including KIBOW Impact Investment II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/27/2018

KIBOW Impact Investment II

Multi-Stage Venture Capital

$4.72M

1

9/1/2015

KIBOW Impact Investment I

Subscribe to see more

$99M

10

Closing Date

4/27/2018

9/1/2015

Fund

KIBOW Impact Investment II

KIBOW Impact Investment I

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Status

Amount

$4.72M

$99M

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.